Background:~-Please refer to National Cancer Institute Surgery Branch (NCI-SB) protocol 18-C-0049, Amendment F.~Objective:~-Under Individual Patient Expanded Access, to treat a patient with metastatic breast cancer with autologous peripheral blood lymphocytes (PBL) that have been transduced with genes encoding T-cell receptors that recognize mutated neoantigens in the autologous cancer.~Eligibility:~Must have measurable, metastatic disease as assessed per RECIST v1.1 criteria.~Must sign the informed consent document.~Willing to sign Durable Power of Attorney Form.~Must have all regulatory approvals prior to start of treatment.~Design:~Please refer to NCI-SB protocol 18-C-0049, Amendment F.~The patient will be treated with a non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine, followed by the infusion of autologous transduced PBL and then high-dose aldesleukin. The patient will also receive pembrolizumab on Day -2 prior to cell administration and additional doses every 3 weeks following cell infusion until the time of disease progression.
A single patient will be treated with Individual Patient TCR-Transduced PBL